Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907830 | PMC |
| http://dx.doi.org/10.1136/bmjgh-2021-005306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
'We need to be part of the solution': lessons from the 2024 PPRI Conference on ensuring access to affordable medicines through innovative policies.
J Pharm Policy Pract
December 2024
College of Pharmacy, Qatar University, Doha, Qatar.
On 25-26 April 2024, the 5th PPRI (Pharmaceutical Pricing and Reimbursement Information) Conference on ensuring equitable access to affordable medicines took place in Vienna (Austria). Twenty-four accepted contributions were presented either as oral presentations or posters, adding to invited keynote lectures, stakeholder debates and workshops. The global multi-stakeholder audience discussed a range of approaches in pharmaceutical policies, which have the potential to successfully and sustainably address current and future challenges in ensuring patient access to affordable medicines globally.
View Article and Find Full Text PDFData-fed, needs-driven: Designing analytical workflows fit for disease surveillance.
Front Vet Sci
January 2023
Department of Computer and Information Sciences, University of Strathclyde, Glasgow, United Kingdom.
Syndromic surveillance has been an important driver for the incorporation of "big data analytics" into animal disease surveillance systems over the past decade. As the range of data sources to which automated data digitalization can be applied continues to grow, we discuss how to move beyond questions around the means to handle volume, variety and velocity, so as to ensure that the information generated is fit for disease surveillance purposes. We make the case that the value of data-driven surveillance depends on a "needs-driven" design approach to data digitalization and information delivery and highlight some of the current challenges and research frontiers in syndromic surveillance.
View Article and Find Full Text PDFImproving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020.
BMJ Glob Health
November 2022
Department of Health Economics, Fudan University School of Public Health, Shanghai, China
China initiated its healthcare reform in 2009 to provide accessible and affordable healthcare to all. We summarised China's drug reforms between 2009 and 2020 using the WHO framework. China has initiated comprehensive drug policies to address different issues, including: (1) issuing or amending major regulations with changes in institutional settings; (2) implementing the marketing authorisation holder system and bioequivalence assessment to improve the quality of drugs; (3) leveraging accelerated market approval and insurance listing to encourage needs-driven innovation and improve the access to new drugs; (4) introducing compulsory licensing to address major public health threats when needed; (5) scaling up the National Essential Medicine Policy and introducing pharmacoeconomic evaluation in National Reimbursable Drug List to promote rational use of medicine and evidence-based selection; (6) applying differentiated pricing strategies and scaling up zero mark-up policies to form a new financing mechanism; (7) adapting bulk procurement and placing strict regulations on the supply chain management to ensure supply and reduce the cost; (8) empowering pharmacists to improve the rational use of medicine; and (9) using procurement and supply chain digital platforms to inform decision and improve efficiency.
View Article and Find Full Text PDFHow to ensure a needs-driven and community-centred vaccination strategy for COVID-19 in Africa.
BMJ Glob Health
February 2021
Medecins Sans Frontieres WaCA, Abidjan, Côte d'Ivoire.
New diagnostics for tuberculosis: fulfilling patient needs first.
J Int AIDS Soc
October 2010
Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerland.
Background: An effective tuberculosis (TB) control programme requires early diagnosis and immediate initiation of treatment. Any delays in diagnosing TB not only impair a patient's prognosis, but also increase the risks of transmitting the disease within the community. Unfortunately, the most recent TB diagnostic tools still depend on high-infrastructure laboratories, making them poorly adapted for use in resource-limited settings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!